Biography
Associate Professor Peter Gorayski is a senior Adelaide-based radiation oncologist recognised for his expertise in complex clinical decision-making, advanced radiotherapy delivery, and the thoughtful application of precision radiation in both cancer and selected non-malignant conditions.
Dual-trained in general practice and radiation oncology, Peter brings broad medical insight to highly specialised cancer care. His malignant practice focuses on central nervous system tumours (brain and spine), head and neck cancers, genitourinary malignancies (prostate, bladder and kidney), and complex skin cancers including non-melanoma skin cancer, Merkel cell carcinoma and melanoma. He has particular expertise in stereotactic radiosurgery (SRS), image-guided precision techniques, and technically nuanced treatment planning where small differences in approach can meaningfully influence long-term outcomes.
Patients are often referred to Peter for complex cases or second opinions where clarity is needed. He is known for careful analysis, balanced discussion of options, and clear explanation of risks and benefits so patients can make informed decisions with confidence.
Peter holds appointments at the Royal Adelaide Hospital and the Australian Bragg Centre for Proton Therapy and Research. He contributes to comparative photon–proton planning and national discussions on appropriate patient selection for particle therapy. His work frequently involves multidisciplinary collaboration, ensuring each patient’s care is aligned across surgical, medical and radiation oncology teams.
He is a Councillor of the Faculty of Radiation Oncology within the Royal Australian and New Zealand College of Radiologists (RANZCR) and current Chair of Targeting Cancer - RANZCR’s national public education initiative. These roles reflect his commitment to maintaining high professional standards and transparent communication about radiotherapy in Australia.
In parallel with his oncology practice, Peter has developed a structured clinical program in functional radiotherapy — the careful use of low-dose radiotherapy for selected inflammatory and proliferative musculoskeletal conditions including osteoarthritis, Dupuytren’s and Ledderhose disease, keloid scarring, plantar fasciitis and related tendinopathies. Patients are assessed comprehensively, and treatment is considered only when it sits appropriately within broader conservative management. Further information is available here.
Peter welcomes referrals for complex oncological management, independent second opinions, and assessment of chronic musculoskeletal conditions where low-dose radiotherapy may be appropriate. Patients and referring clinicians are welcome to contact him directly for discussion prior to formal referral. Private appointments are available promptly, and communication with referrers is timely and detailed.
Publications
Skelton K, Gorayski P, Penfold SN, Murray A, Hamilton D, Yeo A, et al. Australian Particle Therapy Clinical Quality Registry (ASPIRE) protocol (TROG 21.12): a multicentre prospective study on patients with rare tumours treated with radiation therapy. BMJ Open. 2024;14(11):e083044. doi:10.1136/bmjopen-2023-083044. PubMed: https://pubmed.ncbi.nlm.nih.gov/39609005/
Penfold SN, Dell’Oro M, Gorayski P, Hwang E, Le H, et al. Proton-to-photon comparative treatment planning guidelines for the Australian context. J Med Imaging Radiat Oncol. 2023;67(3):320-328. doi:10.1111/1754-9485.13445. PubMed: https://pubmed.ncbi.nlm.nih.gov/36945292/
Hwang E, Thwaites D, Ahern V, Gorayski P, et al. Minimum data elements for the Australian Particle Therapy Clinical Quality Registry (ASPIRE). J Med Imaging Radiat Oncol. 2023;67(4):457-465. doi:10.1111/1754-9485.13489. PubMed: https://pubmed.ncbi.nlm.nih.gov/37148334/
Skelton K, Gorayski P, et al. Travelling overseas for proton beam therapy: experiences and supportive care needs of Australian families. J Med Radiat Sci. 2023;70(2):135-143. doi:10.1002/jmrs.613. PubMed: https://pubmed.ncbi.nlm.nih.gov/36801978/
Doig M, Bezak E, Parange N, Gorayski P, et al. Can we compare the health-related quality of life of childhood cancer survivors following photon and proton radiation therapy? A systematic review. Cancers (Basel). 2022;14(16):3937. doi:10.3390/cancers14163937. PubMed: https://pubmed.ncbi.nlm.nih.gov/36011228/